1 / 11

WHO Programme for International Drug Monitoring & the Uppsala Monitoring Centre

WHO Programme for International Drug Monitoring & the Uppsala Monitoring Centre. Shanthi Pal and Mary Couper Quality Assurance and Safety of Medicines World Health Organization. Birth of modern pharmacovigilance Thalidomide – Phocomelia 1961. 16th World Health Assembly 1963.

galen
Télécharger la présentation

WHO Programme for International Drug Monitoring & the Uppsala Monitoring Centre

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. WHO Programme for International Drug Monitoring&the Uppsala Monitoring Centre Shanthi Pal and Mary Couper Quality Assurance and Safety of Medicines World Health Organization

  2. Birth of modern pharmacovigilanceThalidomide – Phocomelia 1961

  3. 16th World Health Assembly 1963 • Assembly Resolution 16.36 - Clinical and Pharmacological Evaluation of Drugs INVITES Member States to arrange for a systematic collection of information on serious adverse drug reactions observed during the development of a drug and, in particular, after its release for general use.

  4. WHO Programme for International Drug Monitoring TDR HQ-WHO + 6 Regional offices WHO Collaborating Centre, Uppsala HIV/AIDS Malaria MPS National Centres Others

  5. Advisory Committee on Safety of Medicinal Products (ACSoMP) The Advisory Committee on Safety of Medicinal Products shall provide advice on pharmacovigilance policy and issues related to the safety and effectiveness of medicinal products • to the relevant Assistant Director-General in WHO and through him / her • to the Collaborating Centre for International Drug Monitoring (the Uppsala Monitoring Centre), and • to the Member States of WHO.

  6. Pharmacovigilance in WHO HQ • Exchange of Information • Policies, guidelines, normative activities • Country support • Collaborations • Resource mobilisation

  7. 1. Exchange of Information • National Information Officers • Publications (WHO Pharm Newsletter, Restricted Pharm List, Drug Alerts, WHO Drug Information) • International Conference of Drug Regulatory Authorities (ICDRA)

  8. 2. Policies, Guidelines and Normative Activities • Guidelines • The Importance of Pharmacovigilance (2002) • Safety Reporting - A guide to detecting and reporting adverse drug reactions (2002) • Policy perspectives on medicines (Pharmacovigilance) 2004 • Safety monitoring of herbal medicines (2004) • Pharmacovigilance in Public Health • Advisory Committee for the Safe Use of Medicinal Products (ACSoMP)

  9. 10 courses offered in 2008 3. Country support • Training courses on pharmacovigilance (Regional Training Courses, biennial course by UMC and HQ) • Address specific / stated needs: kava, ARVs, antimlalarials…. • Annual Meeting of Pharmacovigilance Centres

  10. 4. Collaborations & Partnerships within WHO Over a 100 million people targeted for either diethylcarbamazine citrate (DEC) plus albendazole or ivermectin plus albendazole. • Malaria • HIV/AIDS • Leprosy • Lymphatic Filariasis • Leishmaniasis • Chagas • Patient Safety • Poisons and Chemicals Safety • Traditional Medicines • Vaccines

  11. 5. Resource Mobilisation • Gates foundation • European commission • Global Fund • Others • Human resources: PvSF

More Related